ABP-450 is under clinical development by AEON Biopharma and currently in Phase II for Spasmodic Torticollis (Cervical Dystonia). According to GlobalData, Phase II drugs for Spasmodic Torticollis (Cervical Dystonia) have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ABP-450’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ABP-450 is under development for the treatment of cervical dystonia and as preventive treatment of episodic, gastroparesis , chronic migraine. The drug candidate is an injectable 900 kDa purified botulinum toxin type A complex. It is administered by intramuscular route.
AEON Biopharma overview
AEON Biopharma, formerly Alphaeon Corp, is a biopharmaceutical company that develops drugs for debilitating medical conditions. It is headquartered in Newport Beach, California, the US.
For a complete picture of ABP-450’s drug-specific PTSR and LoA scores, buy the report here.